Document Detail


Cell cycle and energy metabolism in tumor cells: strategies for drug therapy.
MedLine Citation:
PMID:  21110821     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Recent results obtained from research on the intermediary metabolism of tumor cells have uncovered the biochemical reprogramming that takes place upon malignant transformation. Many features have been highlighted that are currently being exploited for specific chemotherapy. Many more will become available shortly as a consequence of the recognition of potentially useful targets for treatment. General interest in this area can be gauged by the number of recent patents that have been deposited, or are in the process of application. Because the metabolic subversion that is a hallmark of cancer cells involves a disruption of its homeostasis, the regulatory pathways dealt with in this review were broadly divided into those that encompass the main stages of the cell cycle and its various regulatory mechanisms and those that involve the aerobic glycolysis typical of cancer cells. It becomes apparent that both, the cell cycle and the intermediary metabolism are interconnected and rely on reactions many of which are dependent on kinases and phosphatases. Kinases and phosphatases are responsive to cellular redox signaling and may have a key role in determining whether cells progress towards malignant transformation as a result of continuous oxidative stress. The results discussed here underline aspects of the signaling pathways that lend themselves to specific inhibition by natural and synthetic compounds. The mitochondria and its role in programmed cell death are briefly commented, but special emphasis is placed on biochemical regulation at the level of chromatin structure, particularly the reactions that involve acetylation and deacetylation of histones. Within this context, inhibitors that act on histone deacetylases are discussed as promising alternatives to available treatments.
Authors:
Nivea D Amoedo; Tatiana El-Bacha; Mariana F Rodrigues; Franklin D Rumjanek
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Recent patents on anti-cancer drug discovery     Volume:  6     ISSN:  2212-3970     ISO Abbreviation:  Recent Pat Anticancer Drug Discov     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-11-29     Completed Date:  2011-04-01     Revised Date:  2011-11-10    
Medline Journal Info:
Nlm Unique ID:  101266081     Medline TA:  Recent Pat Anticancer Drug Discov     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  15-25     Citation Subset:  IM    
Affiliation:
Universidade Federal do Rio de Janeiro, Instituto de Bioquímica Médica, Centro de Ciências da Saúde, Cidade Universitária, Ilha do Fundão Rio de Janeiro CEP 21941-590, RJ, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Agents / pharmacology,  therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cell Cycle / genetics,  physiology*
Cyclin-Dependent Kinases / genetics,  physiology
Energy Metabolism / drug effects*,  genetics
Enzyme Inhibitors / therapeutic use
Humans
Molecular Targeted Therapy / methods,  trends
Neoplasms / drug therapy*,  genetics
Protein Processing, Post-Translational / drug effects,  genetics
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Enzyme Inhibitors; EC 2.7.11.22/Cyclin-Dependent Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Metabolic targeting of malignant tumors: small-molecule inhibitors of bioenergetic flux.
Next Document:  Informatics of drug synergism in naturally occurring anticancer agents.